Australia’s Behind-The-Counter Experience Shows Little Use For U.S.
This article was originally published in PharmAsia News
Executive Summary
Australia's experience is cited by a U.S. study as demonstrating little use in creating a new class of drugs falling between prescriptions and over-the-counter. That is the conclusion of the Government Accountability Office that studied the projects of Australia, Italy, the Netherlands and United Kingdom. The study determined the experience of those countries showed no need for another class. The class at issue is "behind-the-counter," which proponents have promoted for drugs covering chronic conditions such as asthma, cholesterol and diabetes. (Click here for more